Abstract: An affinity reagent, having: (a) a retaining component such as a structured nucleic acid particle; and (b) one or both of (i) one or more label components attached to the retaining component, and (ii) one or more binding components attached to the retaining component.

Abstract: An affinity reagent, having: (a) a retaining component such as a structured nucleic acid particle; and (b) one or both of (i) one or more label components attached to the retaining component, and (ii) one or more binding components attached to the retaining component.

Abstract: An affinity reagent, having: (a) a retaining component such as a structured nucleic acid particle; and (b) one or both of (i) one or more label components attached to the retaining component, and (ii) one or more binding components attached to the retaining component.

Abstract: Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting probes associated with circulating cells of the tumor that travel to subsurface vasculature of the body. The probe enters a tumor and associates with cells of the tumor before the cells metastasize. A wearable body-mountable device can be worn for a protracted period of time to detect the probe associated with circulating tumor cells in the vasculature at low concentrations and/or at low rates. A body-mounted device could detect the presence of such released, tumor-cell-associated probes to determine a presence or status of a tumor in the body.

Abstract: A method for profiling extracellular vesicles (EV) is provided.

Abstract: Body-mountable devices are provided to detect the presence or status of an analyte in subsurface vasculature of a body by detecting fluorescent reporters that are bound to instances of the analyte in the subsurface vasculature. Such devices further operate to exert an attractive magnetic force on magnetic nanoparticle-containing probes that are configured to bind to the analyte, thus concentrating the analyte proximate the devices by magnetically exerting attractive forces on such probes that are bound to instances of the analyte. The analyte can be an extracellular vesicle that is characteristic of a cancer, and a body-mountable device as described herein could be used to detect such extracellular vesicles in a portion of subsurface vasculature such that a presence or status of a tumor could be determined based on an amount, presence, or other detected property of the extracellular vesicle.

Abstract: Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting one or more properties of a probe located in subsurface vasculature of the body. A wearable body-mountable device can be worn for a protracted period of time to detect a probe in the vasculature at low concentrations and/or at low rates. A body-mountable device can detect properties of the probe that are indicative of whether the probe has interacted with a tumor of the body and determine the presence or status of a tumor in the body based on such detected properties. Additionally or alternatively, the probe could be introduced into the body as a probe aggregate and released from if the probe aggregate is absorbed by a tumor. The presence of released probes could be detected to determine a presence or status of a tumor in the body.

Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

Abstract: A device and system for detecting an antigen present in a sample is provided. The system includes a cartridge and a reader device. The cartridge includes a solid support having an addressable array of at least one type of antibody that is specific for a target antigen and forms a complex in the presence of the target antigen, a substrate having a mounting surface for the solid support, Protein M for competitively displacing the target antigen from the complex, and a housing for protecting the substrate. The reader device is configured to detect the antigen in a liquid sample via interaction with the cartridge.

Abstract: A wearable device mounted on a living body can detect an analyte response signal transmitted from tissue in the living body. The tissue contains at particles conjugated to at least one complex of (i) an antibody labeled with a fluorophore, the labeled antibody having a target analyte binding site; and (ii) protein M labeled with a quencher that is complimentary to the fluorophore of the labeled antibody, wherein the labeled protein M competes with the target analytes for the target analyte binding site on the labeled antibody; wherein the fluorophore and quencher are spectrally matched such that there is a detectable change in the fluorescent signal. The analyte response signal is related to interaction of the target analytes with the complexes. A processor can determine a presence or absence of the analytes based on the analyte response signal.

Abstract: Body-mountable devices are provided to detect the presence or status of an analyte in subsurface vasculature of a body by detecting fluorescent reporters that are bound to instances of the analyte in the subsurface vasculature. Such devices further operate to exert an attractive magnetic force on magnetic nanoparticle-containing probes that are configured to bind to the analyte, thus concentrating the analyte proximate the devices by magnetically exerting attractive forces on such probes that are bound to instances of the analyte. The analyte can be an extracellular vesicle that is characteristic of a cancer, and a body-mountable device as described herein could be used to detect such extracellular vesicles in a portion of subsurface vasculature such that a presence or status of a tumor could be determined based on an amount, presence, or other detected property of the extracellular vesicle.

Abstract: The method for steering a vehicle for loading and unloading a container includes a driver manually driving the vehicle within a handling area outside the limits of a station specifically dedicated to the loading and unloading of a standardized container, and parking the vehicle in a waiting area. Once parked, the vehicle is handled by automatic steering which automatically actuates at least the control of the path thereof and steers in the reverse direction until the vehicle is positioned within the station. The method includes carrying out the loading or unloading of the container, and steering the vehicle manually or automatically in the forward direction until positioned within the waiting area before giving up the automatic steering so that the driver can manually move the vehicle in the forward direction outside the waiting area.

Abstract: The method for steering a vehicle for loading and unloading a container includes a driver manually driving the vehicle within a handling area outside the limits of a station specifically dedicated to the loading and unloading of a standardized container, and parking the vehicle in a waiting area. Once parked, the vehicle is handled by automatic steering which automatically actuates at least the control of the path thereof and steers in the reverse direction until the vehicle is positioned within the station. The method includes carrying out the loading or unloading of the container, and steering the vehicle manually or automatically in the forward direction until positioned within the waiting area before giving up the automatic steering so that the driver can manually move the vehicle in the forward direction outside the waiting area.

Abstract: The invention relates to a vehicle (1) for transporting a container (2), comprising a chassis (3) supported on two axles (40) and capable of receiving at least one container (2), wherein said chassis (4) is further provided with wedges (5) for laterally retaining the container (2), characterized in that said wedges are provided in the form of a protrusion member on the side of the side-members (30) of said chassis (3), in that the rails (70) include, at the bearing surfaces (71) thereof, openings (73) for said side retaining wedges (5) to pass through, wherein the chassis (3) has a width smaller than that of a container (2) so has to pass between two bearing ramps for loading and unloading a container (2). The invention also relates to a facility comprising a plurality of stations and a station base module.

Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.